+

WO1994009034A1 - Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation - Google Patents

Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation Download PDF

Info

Publication number
WO1994009034A1
WO1994009034A1 PCT/AU1993/000524 AU9300524W WO9409034A1 WO 1994009034 A1 WO1994009034 A1 WO 1994009034A1 AU 9300524 W AU9300524 W AU 9300524W WO 9409034 A1 WO9409034 A1 WO 9409034A1
Authority
WO
WIPO (PCT)
Prior art keywords
clot
targeting
anticoagulant
inhibitor
molecule
Prior art date
Application number
PCT/AU1993/000524
Other languages
English (en)
Inventor
Paul Eisenberg
Dennis Brian Rylatt
Carmel Judith Hillyard
Peter Gregory Bundesen
Original Assignee
Agen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agen Limited filed Critical Agen Limited
Priority to EP93922464A priority Critical patent/EP0668875A4/fr
Priority to AU51458/93A priority patent/AU5145893A/en
Publication of WO1994009034A1 publication Critical patent/WO1994009034A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a clot-targeting, anticoagulant molecule, a clot- targeting, anticoagulant binding molecule, compositions for treating a clot in a mammal, methods of treating a clot in a mammal, and kits for treating a clot in a mammal.
  • Blood coagulation is the result of a complex series of events ultimately leading to the proteolytic conversion of circulating soluble fibrinogen to insoluble fibrin. Fibrin formation is a normal physiological response to vascular tissue injury of various aetiology. If the thrombotic process is overwhelming or persistent, partial or total vascular occlusion may result.
  • the clinical consequences of thrombosis include: coronary artery disease (e.g. myocardial ischaemia), cerebral ischaemia (e.g. transient cerebral ischaemic attacks), or peripheral vascular disease (e.g. deep venous thrombosis, peripheral artery occlusion). Atherosclerosis and its complications are the prime cause of death in western society.
  • the atherosclerotic process is associated with extracellular lipid uptake and accumulation within fibroblasts and smooth muscle cells of lipid, resulting in the pathological lesion referred to as an atherosclerotic plaque or atheroma .
  • the factors that promote the development of atherosclerotic plaques are unknown; however, plasma hyperlipaemia, diabetes, hypertension, and cigarette smoking are known risk factors.
  • the natural history of thrombosis is dependent on a balance between procoagulant activity at the site of the thrombus and fibrinolytic activity, which induces dissolution of the thrombus.
  • Clot-associated procoagulant activity is supported by the recruitment of circulating coagulation factors and their activation on the surface of the clot. There is a need for an agent which can prevent clots and which is effective in reducing mortality associated with thrombotic disease, and which is not also associated with untoward bleeding side effects.
  • An object of this invention is to provide a clot-targeting, anticoagulant molecule.
  • compositions for treating a clot in a mammal methods of treating a
  • the inventors realised that it is factor Xa associated with or entrapped within the clot which induces prothrombin activation, thereby increasing local thrombin concentrations, which in turn provides the focus for extension of the thrombus particularly when this enzyme is subsequently exposed by the process of clot dissolution it could easily initiate clot reformation depending on the local balance of fibrinolytic activators and inhibitors.
  • whole-blood clots particularly when platelet rich, induce activation of the coagulation system by at least two phenomena: one is ascribable to the activity of thrombin bound to fibrin, and the other to clot-associated Xa activity.
  • Both clot-associated thrombin and Factor Xa appear to be relatively protected from inhibition by anti-thrombin III or heparin-anti-thrombin III.
  • Factor Xa activity associated with whole-blood clots induces thrombin formation de novo, even when clot-bound thrombin is inhibited.
  • the aim of the present invention is to provide a high concentration of an anticoagulant agent at the surface of a clot.
  • Clot-targeted anticoagulants provide a novel approach for preventing the local progression of clotting while not inhibiting circulating clotting activity.
  • This novel approach has particular applicability to the treatment of coronary thrombosis after angioplasty or thrombolysis, conditions in which the high doses of conventional anticoagulants required to prevent reformation of the coronary clot result in a high incidence of bleeding complications.
  • a clot-targeting, anticoagulant molecule comprising a clot-targeting binding molecule coupled to an anticoagulant.
  • the clot-targeting, anticoagulant molecule may further comprise at least one thrombolytic coupled to the clot binding molecule or may further comprise a thrombolytic coupled to the anticoagulant.
  • the clot-targeting binding molecule may be one capable of coupling to another coagulant molecule in vivo.
  • a clot-targeting binding molecule which is capable of coupling to a coagulant molecule in vivo as well as a composition comprising such a molecule together with an acceptable carrier, diluent, excipient and/or adjuvant.
  • the clot-targeting, anticoagulant molecule of the first embodiment may comprise one or more clot-targeting binding molecules coupled to one or more anticoagulants.
  • composition for treatment of a clot in a mammal comprising a clot-targeting, anticoagulant molecule of the first embodiment together with an acceptable carrier, diluent and/or excipient.
  • treatment of a clot includes treatment to maintain the size of a clot in mammal, treatment to reduce a clot in mammal and a treatment to prevent reformation of a clot in mammal.
  • a method of treating a clot in a mammal comprising administering to a mammal requiring such treatment an effective amount of a clot-targeting, anticoagulant molecule of the first embodiment or a composition of the second embodiment.
  • the method of the third embodiment may further include administering to the mammal an anticoagulant molecule.
  • a method of treating a clot in a mammal comprising administering to a mammal requiring such treatment an effective clot treating amount of a clot-targeting binding molecule and an anticoagulant capable of being bound by the clot- targeting, binding molecule in vivo.
  • the clot-targeting binding molecule may be administered simultaneously or before or after the administration of the anticoagulant capable of being bound by the clot-targeting, anticoagulant molecule.
  • the idea for this embodiment is that the clot-targeting molecule targets and binds to a clot in the mammal and then binds to the anticoagulant capable of being bound to it which prior to now is circulating in the system of the mammal after having been administered to the mammal.
  • the clot-targeting molecule binds to the anticoagulant capable of being bound to it and then targets and binds to a clot in the mammal.
  • a kit for treating a mammal requiring treatment selected from the group consisting of a treatment to treat a clot therein, a treatment to reduce a clot therein and a treatment to prevent reformation of a clot therein, comprising (a) a clot- targeting, binding molecule; and (b) an anticoagulant capable of being bound by the clot-targeting, binding molecule in vitro and/or in vivo.
  • the kit of the fifth embodiment may further comprise an acceptable carrier, diluent and/or excipient.
  • composition of the second embodiment may be administered parenterally, e.g. by injection and by intra-arterial
  • compositions can also be delivered locally by drug delivery catheter devices, in order to increase the dose. It is also possible to administer the compositions orally provided the compositions contain materials such as liposomes which substantially prevent the anticoagulant molecule from being decomposed in the digestive tract.
  • the anticoagulant molecule may be coupled to a carrier which enables it to pass through to the blood stream without substantially decomposing in the digestive tract.
  • the mammal is a bovine, human, ovine, equine, caprine, Leporine, feline or canine vertebrate.
  • the mammal is a human
  • the composition is a pharmaceutical composition
  • the carrier, diluent, excipient and/or adjuvant are pharmaceutically acceptable.
  • composition is typically a veterinary composition and the carrier, diluent, excipient and/or adjuvant are veterinarily acceptable.
  • the clot-targeting, anticoagulant molecule or its salt may be prepared in sterile aqueous or oleaginous solution or suspension.
  • Aqueous solutions or suspensions may further comprise one or more buffering agents
  • Su i table buffering agents include sodium acetate, sodium citrate, sodium borate or sodium tartrate, for example.
  • the dosage form of the clot-targeting, anticoagulant molecule will comp ⁇ se from 0.01% to 99% by weight of the active substance.
  • dosage forms according to the invention will comprise from 0.1% to about 20%, more typically 0.5% to 10% by weight of the active substance.
  • compositions of the second embodiment may be prepared by means known in the art for the preparation of pharmaceutical compositions including blend i ng, grinding, homogenising, suspending, dissolving, emulsifying d i spersing and mixing of the clot-targeting, anticoagulant molecule together with the selected excipient(s), carrier(s), adjuvant(s) and/or diluent(s).
  • a molecule of the first embodiment or a composition of the second embodiment will usually be administered by i n j ect i on.
  • a suitable treatment may comprise the administration of a single dose
  • An alternat i ve suitable treatment may comprise the administration of a single dose or mult i ple doses of the clot-targeting, anticoagulant binding molecule of the first embodiment or a composition of the second embodiment, followed by or preceded by or simultaneously administrating at least one anticoagulant.
  • the treatment will consist X administering from one to five doses da i ly of the clot-targeting, anticoagulant molecule for a period of from one day to several days.
  • a further treatment ⁇ may be given during the lifetime of the patient.
  • the treatment will consist of the administrat i on of the clot-targeting, anticoagulant molecule of the first embodiment or a compos i t i on of the second embodiment for a period of from one day to several days.
  • the administered dosage of the clot-targeting, anticoagulant molecule of the first embodiment or a composition of the second embodiment can vary and depends on several factors, such as the condition of the patient. Dosages w i ll range from O.OOOlmg to 200 mg per kg. Usually, the dose of the act i ve substance will be from O.OOlmg to lOmg per kg of body weight, more typ i cally 0.1 mg - 10 mg per kg of body weight. In the case of a bolus infusion the dose of the active substance is typically 0. lmg to 50mg per kg of body weight.
  • Examples of molecules with affinity for components of clots and wh i ch can target and bind to clots include fibrin targeting and binding proteins e.g. plasmin and plasminogen, antibodies (see Z. H. Oster and P. Som, J. Nucl Med., 1990; 175:79-85, the contents of which are incorporated herein by cross reference) and fragments that bind to cross-linked fibrin and fibrin monomer, or neo-epitopes of fibrin in a clot (e.g. fragment Ei which is a plasmic degradat i on product of human cross-linked fibrin, see for example S.A. Olexa, and A.Z. Budzynski, Proc. Nail. Acad.
  • fibrin targeting and binding proteins e.g. plasmin and plasminogen
  • antibodies see Z. H. Oster and P. Som, J. Nucl Med., 1990; 175:79-85, the contents of which are incorporated herein by
  • epitope is used herein to refer to a binding site on or in a target clot which is specifically recognized by a clot binding molecule, and is not limited to binding sites recognized by antibodies.
  • Other fibrin targeting and binding molecules include D-dimer monoclonal antibody DD 3B6/22, fibrin specific antibodies such as fibrin antifibrin antibody MA 59D8, bifunctional antibodies which bind to fibrin or platelets or other clot components.
  • Examples of molecules with affinity for platelets and which can bind to platelets include platelet binding antibodies, or platelet binding molecules, bifunctional antibodies which bind to activated platelets, activated platelet binding antibodies (e.g. MAb 7E3, MAb 50H.19, MAb PADGEM and MAb P256, see S. F. Rosebrough et al. 1990; 31: 1048 the contents of which are incorporated herein by cross reference), activated platelet binding molecules and an antigen-binding fragment of a clot-targeting antibody, (e.g. MAb P256, F(ab') 2 , and Fab' fragments of MAb P256, see for example A.W.J. Stuttle, J.M. Ritter, A.M.
  • platelet binding antibodies e.g. MAb 7E3, MAb 50H.19, MAb PADGEM and MAb P256, see S. F. Rosebrough et al. 1990; 31: 1048 the contents of which are incorporated herein by cross reference
  • the clot targeting and binding molecule may be any substance having a preferential affinity for a clot component including monoclonal or polyclonal antibodies, enzymes, or other binding proteins or substances (or binding fragments thereof).
  • the CBM is usually an antibody, molecular recognition unit, or an antigen-binding fragment of an antibody, such as a F(ab') 2 , Fab', Fv or VH fragment.
  • Antibodies which recognize at least one of the constituents of clots may be prepared by conventional techniques using clots, or the purified constituents thereof, as immunogens. These antibodies may be monoclonal or polyclonal in nature. Either the intact antibody, or specific
  • the antibody or antibody fragment may be polyvalent, divalent or univalent.
  • anticoagulants including thrombin inhibitors can be included into the molecules of the invention, such as hirudin and hirudin analogues, C- terminal hirudin peptides and analogues, tick anticoagulant peptide (TAP), heparin, coumarin, short peptide inhibitors of thrombin such as small peptide- like inhibitors such as * PPACK (d-phe-pro-arg-chloromethylketone), DuP 714 (ac-d-phe-pro-boroarginine), agratropin (2R, 4R)-4- methyl -1- [N2 -(3-methyl- 1,2,3,4,-tetrahydro -8-quinolinesulphonyl)-L- arginyl]-2- piperidinecarboxylic acid monohydrate, tick anticoagulant peptide or extrinsic pathway inhibitor or tissue pathway inhibitor.
  • TRIP tick anticoagulant peptide
  • heparin heparin
  • coumarin short
  • Fibrinogen receptor antagonists which are suitable anticoagulants for use in the present invention include cyclo(S,S)-N ⁇ -acetyl-Cys-(N ⁇ -methyl)Arg-Gly-Asp-Pen NH 2 Ali et al., EP 0341 915, cyclo(S,S)-(2-mercapto) benzoyl-(N ⁇ -methyl)Arg-Gly- Asp-(2-mercapto), EP Application No.
  • Patent 4,952,562 Ali et al., PCT US 90/06514; Alig. et al., EP 0 381 033; and Alig et al., EP 0 384 362; the contents of all of which are incorporated herein by cross reference as well as and the cyclic peptides.
  • the anticoagulant included in the molecules of the invention, acts as an antithrombin agent and/or inhibitor of earlier steps in the coagulation cascade such as factor Xa (for example TAP), factor Va, factor X, factor IXa, factor Villa, factor Vila, the prothrombinase complex, vitamin-K-dependent
  • anticoagulants include factor Xa inhibitor including TAP, factor Va inhibitor, factor Villa inhibitor, factor Vila inhibitor, factor IXa inhibitor, prothrombinase complex inhibitor, vitamin-K-dependent gamma carboxylation of prothrombin inhibitor, factor X inhibitor, factor VII inhibitor, factor V inhibitor, factor Vffl inhibitor, and factor IX inhibitor.
  • Thrombolytic agents such as urokinase, scuPA streptokinase or tPA may also be coupled to the clot binding molecule of the invention to prevent arterial wall intimal proliferation.
  • Anti growth factors e.g. anti-PDGF and other targeted growth factors e.g. FGF's to induce reendothelialization
  • the clot-targeting, anticoagulant molecule of the invention may be a single molecule with clot binding and anticoagulant moieties, or a complex of two or more molecules.
  • the term "molecule” will be used to cover both moieties and molecules, and "conjugate” to cover both a single hybrid molecule with clot binding and anticoagulant moieties and two conjugated molecules one of which has clot binding behaviour and the other of which has anticoagulant behaviour.
  • the conjugate is obtained by coupling a CBM to an anticoagulant (ACM).
  • ACM anticoagulant
  • TMB thrombolytic
  • TBM thrombolytic binding molecule
  • the CBM, the ACM and optionally the TMB and/or TBM may be coupled together directly or indirectly (e.g. via a linker molecule), and by covalent or non- covalent means (or a combination thereof).
  • the clot-targeting, anticoagulant binding molecule of the invention may be a single molecule with clot binding and anticoagulant binding moieties, or a complex of two or more molecules.
  • the conjugate is obtained by coupling a CBM to an anticoagulant binding molecule (ACBM).
  • ACBM anticoagulant binding molecule
  • the conjugate is obtained by coupling a CBM to an ACBM and a TMB and/or TBM.
  • the CBM, the ACBM and optionally the TMB and/or TBM may be coupled together directly or indirectly (e.g. via a linker molecule), and by covalent or non-covalent means (or a combination thereof).
  • anticoagulant molecule such as [anticoagulant-antibody to clot], [anticoagulant-antibody to clot-thrombolytic agent], [anticoagulant-thrombolytic- antibody to clot] and [thrombolytic-anticoagulant-antibody to clot]
  • antibody is understood to encompass clot targeting and binding monoclonal or polyclonal antibodies and clot targeting and binding fragments thereof in particular, F(ab') , Fab', Fv or VH fragments, especially D-dimer including MAb DD-3B6/22, F(ab') 2 fragments of MAb DD-3B6/22, Fab' fragments of MAb DD-3B6/22, all the fibrin targeting monoclonal antibodies disclosed in U.S.
  • Patent No. 4,758,524 (the contents of all of which is incorporated herein by cross reference), monoclonal antibody DD-1D2/48, F(ab') 2 fragments of MAb DD-1D2/48, Fab' fragments of MAb DD-1D2/48, monoclonal antibody DD-1C3/108, F(ab') 2 fragments of MAb DD-1C3/108, Fab' fragments of MAb DD-1C3/108, and all the other fibrin targeting and binding antibodies disclosed elsewhere in this specification, and any other monoclonal either human or mouse or other mammal which has specificity for fibrin or D dimer but not fibrinogen or fragments thereof, fibrin specific antibodies such as fibrin antifibrin antibody MA 59D8, monoclonal antibody DD-1C3/108, bifunctional antibodies which target and bind to fibrin or target and bind to platelets, particularly activated platelets or other clot components or a clot antigen-binding fragment of an antibody, such as a F(a
  • the antibody or antibody fragment may be polyvalent, divalent or univalent.
  • MAb DD-3B6/22 is commercially available from Agen Biomedical Limited, 11 Durbell Street, Acacia Ridge, Qld 4110 and Agen Inc., 20 Waterview Boulevard, Parsippany, New Jersey, U.S.A. 07054.
  • MAb DD-1D2/48 and MAb DD1C3/108 are also available from these sources.
  • SPDP N-Succinimidyl-3,2-(pyridyldithio) propionate
  • MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
  • cross linking agents include cross-linking agents include 4,4'- dithiobisphenylazide, dithiobis-(succinimidylpropionate), 2- iminothiolane, dimethyl-3,3'-dithiobispropionimidate.2HCl,
  • the coupling may also be noncovalent, for example, b y (a) attach i ng biotin to one and avidin (or streptavidin) to the other), (b) attaching an ant i antibod y to one, which then binds the other, (c) attaching Protein A to one, which then binds the Fc portion of the other, or (d) attaching a sugar to one and a corresponding lectin to the other.
  • b y (a) attach i ng biotin to one and avidin (or streptavidin) to the other), (b) attaching an ant i antibod y to one, which then binds the other, (c) attaching Protein A to one, which then binds the Fc portion of the other, or (d) attaching a sugar to one and a corresponding lectin to the other.
  • the binding characteristics of the CBM and TBM the anticoagulant properties of the ACM and the thrombolytic propert i es of the TMB should be changed as little as possible. It may be advantageous to provide a spacer moiety between the CBM and ACM and optionally TMB and TBM to reduce steric hindrance.
  • the CBM may be coupled directly to an ACM
  • the CBM may be coupled directly to an TMB and/or TBM or indirectly via coupling to an ACM coupled to the CBM.
  • the binding characteristics of the CBM, ACBM and TBM and the thrombolytic properties of the TMB should be changed as little as possible. It may be advantageous to provide a spacer moiety between the CBM and ACBM and optionally TMB and TBM to reduce steric hindrance.
  • the CBM may be coupled to directly to an ACBM or indirectly via an TMB and/or TBM.
  • the CBM may be coupled directly to an TMB and/or TBM or indirectly via coupling to an ACBM coupled to the CBM.
  • a CBM/ACM conjugate may be an antibody coupled to an anticoagulant.
  • One method of constructing such a conjugate is the following: (a) preparing F(ab')' 2 fragments of a selected antibody to a clot component by pepsin digestion; (b) reducing and treating the fragments with Ellman's reagent to produce Fab' fragments of the selected antibody; and (c) coupling the Ellman's reagent-treated Fab' fragment to a selected anticoagulant and optionally a TMB and/or TBM, to produce a clot-targeting, anticoagulant molecule.
  • the CBM/ACBM conjugate may be a hybrid antibody.
  • One method of constructing such a conjugate is the following: (a) preparing F(ab')' 2 fragments of a selected antibody to a clot component by pepsin digestion; (b) reducing and treating the fragments with Ellman's reagent to produce Fab' fragments of the selected antibody; (c) thiolysing a selected anticoagulant-specific antibody or a selected anti-coagulant antibody; and (d) coupling the thiolated Fab' fragment to the Ellman's reagent-treated Fab' fragment to produce a hybrid anti-clot antibody anticoagulant specific antibody conjugate.
  • the CBM/ACBM/TBM conjugate may also be a hybrid antibody.
  • One method of constructing such a conjugate is the following: (a) preparing F(ab')' fragments of a selected antibody to a clot component by pepsin digestion; (b) reducing and treating the fragments with Ellman's reagent to produce Fab' fragments of the selected antibody; (c) thiolysing a selected anticoagulant- specific antibody or a selected anti-coagulant antibody; (d) thiolysing a selected thrombolytic-specific antibody or a selected thrombolytic antibody; and (e) coupling the thioylated Fab' fragments of (c) and (d) to the Ellman's reagent- treated Fab' fragment to produce a hybrid anti-clot antibody anticoagulant specific antibody and thrombolytic-specific antibody conjugate.
  • SUBSTITUTE SHEET j Another method for constructing a CBM/ ACBM conjugate, comprises: (a) treating an anti-clot component MAb-producing hybridoma and an anticoagulant-specific MAb-producing hybridoma with a distinct site-specific irreversible inhibitor of macromolecular biosynthesis; preferably the inhibitor is selected from the group consisting of emetine, actinomycin D, hydroxyurea, ouabain, cycloheximide, edine and sparsomycin; (b) fusing the two different MAb-producing hybridomas with polyethylene glycol to produce a heterohybridoma; (c) cloning the fused cells by any of a number of cloning methods such as isolation in soft agarose or by limiting dilution; (d) selecting cloned heterohybridomas secreting chimeric anti-clot component antibody- antigen specific antibody with a screening assay appropriate to the antibodies; (e) purifying the antibody product by affinity pur
  • the hybrid or chimeric antibody of the present invention thus comprises two "half molecules," one with specificity for clot component(s) (the CBM) and the other with specificity for an anticoagulant (the ACBM) .
  • the antibody's own disulfide bonds couple the ACBM to the CBM to form an appropriate conjugate.
  • Such a hybrid antibody, or F(ab') 2 fragment of such a molecule has advantages which include ease of preparation, the preservation of the correct stoichiometry and stereochemistry of both antibodies and the retention of the binding affinity of each fragment.
  • the use of a peptide to bind to the clot has the further advantage that the entire conjugate may be prepared without any need for a bifunctional coupling agent.
  • a DNA sequence encoding the clot-binding peptide and the anticoagulant-binding peptide as a single transcriptional unit is provided, and the desired conjugate is expressed as a fusion protein, with the two moieties joined by a simple peptide bond, or with a peptide spacer of desired length.
  • One particularly preferred example is a DNA sequence encoding a clot-binding antibody fragment (which could be just the binding site, not a complete Fab) and anticoagulant antibody (which could be just the binding site, not a complete
  • the desired conjugate is expressed as a fusion protein, with the two moieties joined by a simple peptide bond, or with a peptide spacer of desired length.
  • the divalent peptide may be prepared by direct chemical synthesis.
  • the anticoagulant and thrombolytic may be molecules which may be activated in vivo on attachment to the clot by light irradiation (particularly far
  • anticoagulants including thrombin inhibitors are targeted to a clot by combining them with clot binding molecules to form a hybrid molecule one part of which can bind to a clot component such as fibrin or platelets with high affinity and the other part being able to bind and inactivate thrombin or other procoagulant molecules located at or within the clot.
  • hybrid molecules can be constructed which comprise one half monoclonal antibody with high affinity for a clot component and one half a specific thrombin inhibitor such as a hirudin.
  • the anticoagulant inactivates thrombin and/or other procoagulant molecules located either bound to the clot surface or activated in the vicinity of the clot.
  • This approach has two major advantages over the current antithrombotic agents. Firstly, it targets the clot and thus brings anticoagulant to the clot where thrombolysis causes a local high concentration of procoagulant thrombin. Thus, it enhances the specificity of anticoagulants for ongoing thrombotic processes and increases the local concentration of anticoagulants. Second, the half-life of the desired anticoagulant effect is increased permitting shorter administration of the anticoagulant. These effects result in a decrease in the amount of drug that must be administered, an increase in efficacy and an increase in safety.
  • a clot targeted anticoagulant molecule is made by coupling the fibrin specific monoclonal antibody DD-3B6/22 with an anticoagulant peptide (for example PPACK, hirulog or hirudin) or with an anticoagulant (for example heparin, or coumarin) and a thrombolytic agent (example tPA or urokinase).
  • an anticoagulant peptide for example PPACK, hirulog or hirudin
  • an anticoagulant for example heparin, or coumarin
  • a thrombolytic agent example tPA or urokinase
  • a pharmaceutical composition for treatment selected from the group consisting of a treatment to treat a clot therein, a treatment to reduce a clot therein and a treatment to prevent reformation of a clot therein is then made by mixing the clot targeted anticoagulant molecule or the clot targeted anticoagulant thrombolytic molecule together with a pharmaceutically acceptable carrier, diluent or excipient.
  • a human may be treated to reduce the clot therein by administering to the human requiring treatment such as treatment to treat a clot therein, treatment to reduce a clot therein and treatment to prevent reformation of a clot therein, an effective clot treating amount of the pharmaceutical composition.
  • Use of monoclonal antibody DD-3B6/22 is especially advantageous to target a clot as there is no cross reaction of the monoclonal antibody with fibrinogen, fibrinogen fragment D, fibrinogen fragment E or non
  • dosage forms in accordance with the invention are as follows:
  • Clot-targeting, anticoagulant molecule 0.1 to 10 mg/kg, generally 0.5 to 9mg/kg
  • Fab-SH fragment of DD-3B6/22 was prepared by the method described by John eLfi! Throm. Res. 58 273-281 1990. Briefly purified antibody was digested with pepsin and F(ab')2 fragments purified. Fab-SH is prepared from
  • the anti-thrombin peptide derivative PPACK was reacted with SPDP (Pharmacia) under the conditions recommended by the manufacturer. Purification of the N-terminally modified derivative was carried out by reverse phase chromatography on a C-18 column using a gradient of 0-60% acetonitrile containing 0.1% trifluoracetic acid. The SPDP-labelled peptide was recovered after freeze drying. (c) Formation of Fab-PPACK derivative.
  • the pH of the Fab-SH solution was adjusted to pH 7.0 by the addition of 0.2M Sodium phosphate buffer pH 8.0. 10ml of 2mg ml fragment was reacted with
  • This assay measures the ability of the reagent to inhibit the action of thrombin on the thrombin specific chromogenic substrate S-2238. Inhibitors of this
  • Targeted anticoagulant reagent inhibits the activity of thrombin on the chromogenic substrate in a dose dependant manner.
  • the Fab fragment of the antibody or the antibody fragment alone has no such inhibitory activity (not shown). 3. Thrombin clotting time inhibition assay
  • This assay measures the ability of the reagent to inhibit the activity of thrombin to form clots in plasma.
  • Thrombin clotting time was measured as described in "Practical Haematology", Dacie JV and Lewis SM eds, Churchill Livingstone Publishers Edinburgh UK 1 84 pp 218-219.
  • SUBSTITUTE SHEET This assay measures the ability of clot bound targeted anticoagulant reagent to inhibit clot extension.
  • Preparation of plasma and whole blood clots and measurement of thrombin-dependant clot associated procoagulant activity was carried out essentially as described by Eisenberg et al J. Clin. Invest. 91 1877- 1883 1993 (incorporated herein by cross reference). Briefly plasma clots were developed in barium-adsorbed plasma repeated with CaCl 2 to a final concentration of 25mM. The clot formed was washed extensively and then incubated in a solution of citrated plasma containing variable concentrations of inhibitor or buffer as a control.
  • Clots incubated with targeted anticoagulant reagent are able to inhibit the clot associated procoagulant activity.
  • the Fab-SH fragment of DD-3B6/22 was prepared by the method described by John eL_a] Throm. Res. 58 273-281 1990 except that the Fab-TNB derivative was prepared instead of the Fab-SH derivative. Briefly purified antibody was digested with pepsin and F(ab') 2 fragments purified. Fab-SH is prepared from F(ab') 2 by mild reduction with beta mercaptoethylamine and reaction with lO M Ellman's reagent (5,5' Dithio-bis[-2-nitrobenzoic acid]). The derivative was purified by gel filtration chromatography in a 0.2M phosphate buffer at pH 7.4.
  • Peptides were prepared by the Merrifield procedure (Hodges and Merrifield Anal.Biochem. 65 7241 195) essentially as described by Kemp et al Science 241 1352- 1354 1988.
  • the peptides prepared were based on the hirulog structure (Manganore et al Biochemistry 29 7095-7101 1990), but with addition of a cysteine residue to enable conjugation of the peptide to the hinge region of the
  • Fab-TNB (-2mg/ml) was a incubated with the cysteine containing hirulog derivatives at a 1:20 molar ratio. The reaction mixture turned yellow in colour after 2min. The reaction was then stopped with the addition of 50 ⁇ l of 300mM iodoacetamide. This was wrapped in foil and incubated for 30min at room temperature. Unreacted hirulog derivative was removed from conjugate by gel filtration chromatography on a column of Ultragel Ac44 in PBS.
  • the thrombin clotting assay was used to establish that the conjugate contained anticoa ulant activit .
  • RNA messenger RNA
  • single and double stranded complementary DNA may be synthesised.
  • the ds-cDNA may be cloned into lambda-gtlO arms and packaged into a phage library.
  • the heavy chain clone gamma-M/l.T (Tyler et al., Proc. Natl. Acad. of Sci., 1982; 79: 2008-2012) and the light chain clone pH76-kap ⁇ a-10 (Adams et al., Biochem., 1980; 19: 2711-2719) were used to source ds-DNA inserts for the screening of the gtlO library.
  • N-terminal sequence of the 3B6/22 light chain N- terminal residues from the intact 3B6/22 Ig may be removed sequentially by Ed an degradation in an Applied Biosystems sequencer. The N-terminal sequence of the light chain can be thus deduced from the mixed sequence by comparison with the sequence of the cloned heavy chain.
  • the variable region of the kappa light chain not present in gtlO library clones may be amplified by PCR from ss-cDNA.
  • the redundant, forward (sense) primer N960 may be designed from the deduced amino terminal kappa sequence.
  • a typical reaction 100 ⁇ l volume
  • a typical reaction 100 ⁇ l volume
  • a typical reaction 100 ⁇ l volume
  • a mixed A,C,G and T deoxynucleotide dNTP solution
  • each primer 10 pMolar each
  • 1 ⁇ l of internal primers 0.05-0.1 pM
  • Mg + + to a final concentration of 1-5 mM a reaction buffer appropriate for the particular polymerase chosen (supplied by manufacturer), and water to 100 ⁇ l.
  • the reactants were mixed and
  • paraffin oil Sigma biochemical
  • a thermal cycler Corbett Research, Australia.
  • the general strategy for each of the examples consisted of a denaturation step at 93°C (usually 1 minute), an annealing step between 50 and 65°C for 1 minute and an extension step at 72°C for 2 minutes. Annealing temperatures were adjusted as required to give final product.
  • Vb variable domain
  • the product was digested with Thai and Eco Rl, and cloned into the Msc 1/Eco Rl-digested expression vectors pPOW (Power et al, Gene, 1992; 113: 95-99) and transformed into E coli strains TG-1 (Gibson TJ, 1984, "Studies on the Epstein-Barr virus genome", PhD thesis, Cambridge University, England) and 14 ⁇ l respectively. 3.
  • Transformed E coli were screened for the presence of plasmids carrying the Vh gene fragment and selected clones (hereafter referred to as pP3B6Vh pr [G3B6Vh) sequenced to check the integrity of the cloning procedure.
  • ( ii ) Amplification and cloning of the light chain variable domain and construction of a composite single-chain antibody domain (scFv ) .
  • Oligonucleotide primers were synthesised to simultaneously amplify (as in i(l) above) and add to the cloned light chain gene, in a PCR amplif i cation reaction, a Bst E2 site and a sequence coding for a linker (amino acid sequence - (GGGGS)3-) at the 5' end and a peptide epitope-Eco Rl sequence at the 3' end.
  • the product was digested with Bst E2 and Eco Rl and cloned into the Bst E2,/Eco Rl digested plasmids described as pP3B6Vh pr pG3B6Vh above and transformed into the E coli strains described in i above.
  • Oligonucleotide NSfil5 was used to add a Sfi 1 restriction site to the 5' end of the scFv gene construct in P P3B6scFv, and (NVKFORNOT) was used to add a Not 1 site to the 3' end of the scFv domain.
  • the product was digested with these restriction enzymes and cloned into the likewise restricted vector pHFA, a derivative of the vector pHEN, and the construct transferred into the E coli strain HB2151, a non-supE phenotypic strain.
  • Clones, referred to as pHFA3B6, were identified by hybridisation and were tested for expression of a
  • Recombinant E coli were grown in lOmls of 2X-YT medium (10 gm yeast extract, 19 gm tryptone, 5 gm NaCl per litre overnight. Overnight cultures were diluted to an ODgrjO 0.5 into 100 ml of fresh medium and grown to mid- log phase (OD600 0.5-0.9). Cultures of pG3B6scFv and pHFA 3B6 were induced upon the addition of isopropyl-B-D-thiogalactopyranoside; (IPTG; Sigma 15502) to a concentration of ImM, and growth continued at 30-37°C as required for a further 4 hours. pHFA 3B6/22 cultures were maintained at 30°C for up to 24 hours post-induction.
  • 2X-YT medium 10 gm yeast extract, 19 gm tryptone, 5 gm NaCl per litre overnight. Overnight cultures were diluted to an ODgrjO 0.5 into 100 ml of fresh medium and grown to mid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une molécule anticoagulante ciblant les caillots, une molécule de liaison anticoagulante qui cible les caillots et des compositions, procédés et nécessaires permettant de traiter un caillot chez un mammifère. La molécule anticoagulante ciblant les caillots comprend une molécule de liaison ciblant les caillots couplée à un anticoagulant. Elle peut comprendre en outre un thrombolytique couplé soit à la molécule de liaison ciblant les caillots soit à l'anticoagulant.
PCT/AU1993/000524 1992-10-12 1993-10-12 Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation WO1994009034A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93922464A EP0668875A4 (fr) 1992-10-12 1993-10-12 Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation.
AU51458/93A AU5145893A (en) 1992-10-12 1993-10-12 Clot directed anticoagulant, process for making same and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL5234 1992-10-12
AUPL523492 1992-10-12

Publications (1)

Publication Number Publication Date
WO1994009034A1 true WO1994009034A1 (fr) 1994-04-28

Family

ID=3776468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1993/000524 WO1994009034A1 (fr) 1992-10-12 1993-10-12 Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation

Country Status (3)

Country Link
EP (1) EP0668875A4 (fr)
WO (1) WO1994009034A1 (fr)
ZA (1) ZA937553B (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000171A3 (fr) * 1996-07-01 1998-06-04 Redcell Canada Inc Excipients endogenes conjugues prolongeant la duree de vie des anti-thrombines
WO2003000736A1 (fr) * 2001-06-26 2003-01-03 Agen Biomedical Limited Anticorps humanises derives de dd-3b6/22, specifiques du fragment d-dimere de la fibrine
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
WO2007011363A2 (fr) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
EP1986682A2 (fr) * 2006-02-06 2008-11-05 The Burnham Institute for Medical Research Procedes et compositions lies au ciblage de tumeurs et de plaies
WO2009140598A1 (fr) 2008-05-16 2009-11-19 Bayer Healthcare Llc Facteurs de coagulation ciblés et procédés d'utilisation de ceux-ci
US7875596B2 (en) 2004-05-19 2011-01-25 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2018093766A1 (fr) 2016-11-16 2018-05-24 Bayer Healthcare Llc Facteur viii ciblé de globules rouges et son procédé d'utilisation
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2025002476A1 (fr) * 2023-06-27 2025-01-02 广东粤港澳大湾区国家纳米科技创新研究院 Médicament ciblé ainsi que son procédé de préparation et son utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396188A1 (fr) * 1989-05-01 1990-11-07 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Anticorps contre la fibrine, peptides immunogènes convenant à la préparation de ces anticorps, méthode de détermination de fibrine et préparations pharmaceutiques à base de ces anticorps
AU5815990A (en) * 1989-05-17 1990-12-18 Scripps Clinic And Research Foundation Polypeptide-antibody conjugate for inhibiting cell adhesion
AU6179090A (en) * 1989-08-24 1991-04-03 Australian Nuclear Science & Technology Organisation Radio-labelled antibodies for imaging
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
AU7766391A (en) * 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
WO1993007174A1 (fr) * 1991-10-01 1993-04-15 The General Hospital Corporation Proteine dependant de l'activation et exprimee sur la surface de plaquettes activees et les anticorps associes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001332A1 (fr) * 1988-08-10 1990-02-22 Cetus Corporation Conjugues d'activateur plasminogene-heparine
EP0449879A1 (fr) * 1988-11-25 1991-10-09 Centocor, Inc. Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques
CA2051436A1 (fr) * 1989-04-03 1990-10-04 Christoph Bode Substances immunoconjuguees specifiques des plaquettes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
EP0396188A1 (fr) * 1989-05-01 1990-11-07 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Anticorps contre la fibrine, peptides immunogènes convenant à la préparation de ces anticorps, méthode de détermination de fibrine et préparations pharmaceutiques à base de ces anticorps
AU5815990A (en) * 1989-05-17 1990-12-18 Scripps Clinic And Research Foundation Polypeptide-antibody conjugate for inhibiting cell adhesion
AU6179090A (en) * 1989-08-24 1991-04-03 Australian Nuclear Science & Technology Organisation Radio-labelled antibodies for imaging
AU7766391A (en) * 1990-04-23 1991-11-11 Corvas International N.V. Thrombus-specific antibody derivatives
WO1993007174A1 (fr) * 1991-10-01 1993-04-15 The General Hospital Corporation Proteine dependant de l'activation et exprimee sur la surface de plaquettes activees et les anticorps associes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHOLLET-MARTIN, S. et al., Thrombosis Research, Volume 52, 1988 (Pergamon Press PLC, USA), "Binding of an Anti D Dimer Monoclonal Antibody to Endotoxin-Activated Monocytes. Demonstration by Immunogold-Silver Staining", see pages 1 to 9. *
DERWENT ABSTRACT Accession No. 90-089876, Class B05; & US,I,H735 (US DEPT OF ENERGY) 6 February 1990 (06.02.90). *
GARGAN, P.E. et al., Thrombosis and Haemostasis, Volume 59, No. 3, 1988 (F.K. Schattauer Verlagsgesellschaft mBH, Germany), "A Fibrin Specific Monoclonal Antibody which Interferes with the Fibrinolytic Effect of Tissue Plasminogen Activator", see pages 426 to 431. *
HOLVOET, P. et al., Thrombosis and Haemostasis, Volume 61, No. 2, 1989 (F K Schattaver Verlagsgesellschaft mBH, Germany), "Binding Properties of Monoclonal Antibodies against Human Fragment D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model in Rabbits", see pages 307 to 313. *
PALABRICA, T.M. et al., Proceedings of the National Academy of Sciences, USA, Volume 86, February 1989 (National Academy of Sciences, USA), "Thrombus Imaging in a Primate Model with Antibodies Specific for an External Membrane Protein of Activated Platelets", see pages 1036 to 1040. *
See also references of EP0668875A4 *
TYMKEWYCZ, P.M. et al., Thrombosis Research, Volume 54, 1989 (Pergamon Press PLC, USA), "Imaging of Human Thrombi in the Rabbit Jugular Vein: I: Comparison of Two Fibrin - Specific Monoclonal Antibodies", see pages 411 to 421. *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000171A3 (fr) * 1996-07-01 1998-06-04 Redcell Canada Inc Excipients endogenes conjugues prolongeant la duree de vie des anti-thrombines
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
WO2003000736A1 (fr) * 2001-06-26 2003-01-03 Agen Biomedical Limited Anticorps humanises derives de dd-3b6/22, specifiques du fragment d-dimere de la fibrine
US7087724B2 (en) 2001-06-26 2006-08-08 Agen Biomedical Ltd Carrier molecules
AU2002318960B2 (en) * 2001-06-26 2008-05-15 Agen Biomedical Limited Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin
US7459143B2 (en) 2001-06-26 2008-12-02 Agen Biomedical Ltd. Carrier molecules
US7875596B2 (en) 2004-05-19 2011-01-25 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
WO2007011363A2 (fr) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
WO2007011363A3 (fr) * 2004-08-11 2007-07-05 Trubion Pharmaceuticals Inc Proteines de fusion a domaine de liaison
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2510943A1 (fr) * 2006-02-06 2012-10-17 The Burnham Institute for Medical Research Procedes et compositions lies au ciblage detumeurs et de plaies
EP1986682A4 (fr) * 2006-02-06 2010-03-03 Burnham Inst Medical Research Procedes et compositions lies au ciblage de tumeurs et de plaies
EP1986682A2 (fr) * 2006-02-06 2008-11-05 The Burnham Institute for Medical Research Procedes et compositions lies au ciblage de tumeurs et de plaies
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9422362B2 (en) 2008-05-16 2016-08-23 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
US10035840B2 (en) 2008-05-16 2018-07-31 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
WO2009140598A1 (fr) 2008-05-16 2009-11-19 Bayer Healthcare Llc Facteurs de coagulation ciblés et procédés d'utilisation de ceux-ci
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2018093766A1 (fr) 2016-11-16 2018-05-24 Bayer Healthcare Llc Facteur viii ciblé de globules rouges et son procédé d'utilisation
US11104718B2 (en) 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
WO2025002476A1 (fr) * 2023-06-27 2025-01-02 广东粤港澳大湾区国家纳米科技创新研究院 Médicament ciblé ainsi que son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
EP0668875A1 (fr) 1995-08-30
EP0668875A4 (fr) 1999-05-26
ZA937553B (en) 1994-05-03

Similar Documents

Publication Publication Date Title
US5759542A (en) Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
JP3495365B2 (ja) ブタ第ｖｉｉｉ因子ａ２ドメインをコードするｄｎａ
US5663060A (en) Hybrid human/animal factor VIII
Chen et al. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site‐specific mutagenesis to improve potency and selectivity
US5639726A (en) Peptide mediated enhancement of thrombolysis methods and compositions
EP3013366B1 (fr) Thérapie combinée utilisant un inhibiteur du facteur xii et l'inhibiteur c1
WO1994009034A1 (fr) Anticoagulant ciblant les caillots, ses procedes de fabrication et d'utilisation
ES2283308T3 (es) Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
AU703256B2 (en) Bradykinin analogs as selective thrombin inhibitors
JPH04505753A (ja) 血小板活性化阻害ポリペプチドを製造する方法ならびにそれを用いた方法，組合せおよび組成物
JPH06184196A (ja) ビトロネクチン由来合成ペプチドおよびそれらを含有する医薬組成物
WO2004022598A1 (fr) Proteine hybride assurant les fonctions d'hemolyse et d'anticoagulation
JPH0193535A (ja) 線溶活性増強剤
JP2001502895A (ja) アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
KR100335536B1 (ko) 트롬빈억제제
WO1993013133A1 (fr) ANTICORPS DE TYPE HUMAIN REACTIF A GPIIb/IIIa
JPH11502508A (ja) 医薬製剤の製造における活性化プロテインｃの使用
CA1341377C (fr) Composition, ainsi qu'une methode pour accelerer la lyse des caillots
EP2600891B1 (fr) Protéines de fusion recombinants possédant des propriétés thrombolytiques et anticoagulantes
Develter et al. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
US5443827A (en) Fibrin-targeted inhibitors of thrombin
Naessens et al. Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition
US5620688A (en) Methods of inhibiting the activation of Factor XIII
AU5145893A (en) Clot directed anticoagulant, process for making same and methods of use
US5372812A (en) Composition and method for acceleration of clot lysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993922464

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993922464

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 411671

Date of ref document: 19950913

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993922464

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载